176 related articles for article (PubMed ID: 35406630)
1. Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma.
Wang Q; Tan Y; Jiang T; Wang X; Li Q; Li Y; Dong L; Liu X; Xu G
Cells; 2022 Mar; 11(7):. PubMed ID: 35406630
[TBL] [Abstract][Full Text] [Related]
2. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
[TBL] [Abstract][Full Text] [Related]
3. Lipid Remodeling in Hepatocyte Proliferation and Hepatocellular Carcinoma.
Hall Z; Chiarugi D; Charidemou E; Leslie J; Scott E; Pellegrinet L; Allison M; Mocciaro G; Anstee QM; Evan GI; Hoare M; Vidal-Puig A; Oakley F; Vacca M; Griffin JL
Hepatology; 2021 Mar; 73(3):1028-1044. PubMed ID: 32460431
[TBL] [Abstract][Full Text] [Related]
4. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
5. [Cancer metabolism: a novel perspective on precision diagnosis and treatment for liver cancer].
Ning Z; Tan G
Zhonghua Wai Ke Za Zhi; 2020 Jan; 58(1):31-36. PubMed ID: 31902167
[TBL] [Abstract][Full Text] [Related]
6. Loss of PTEN expression is associated with PI3K pathway-dependent metabolic reprogramming in hepatocellular carcinoma.
Zhao C; Wang B; Liu E; Zhang Z
Cell Commun Signal; 2020 Aug; 18(1):131. PubMed ID: 32831114
[TBL] [Abstract][Full Text] [Related]
7. Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
Sun J; Ding J; Shen Q; Wang X; Wang M; Huang Y; Zhang X; Zhu H; Zhang F; Wu D; Peng M; Zhang Z; Yuan Y; Li W; She ZG; Zhang XJ; Li H; Zhang P; Huang Z
J Hepatol; 2023 Mar; 78(3):627-642. PubMed ID: 36462680
[TBL] [Abstract][Full Text] [Related]
8. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
[TBL] [Abstract][Full Text] [Related]
9. Integration of metabolomics and expression of enolase-phosphatase 1 links to hepatocellular carcinoma progression.
Zhuang H; Qiang Z; Shao X; Wang H; Dang Y; Wang Z; Wu F; Wei W; Li Y
Theranostics; 2019; 9(12):3639-3652. PubMed ID: 31281503
[TBL] [Abstract][Full Text] [Related]
10. Use of cellular metabolomics and lipidomics to decipher the mechanism of Huachansu injection-based intervention against human hepatocellular carcinoma cells.
Wu H; Cheng H; Luo S; Peng C; Zhou A; Chen Z; Wu H; Li Q
J Pharm Biomed Anal; 2022 Apr; 212():114654. PubMed ID: 35158184
[TBL] [Abstract][Full Text] [Related]
11. Compound Kushen Injection intervenes metabolic reprogramming and epithelial-mesenchymal transition of HCC via regulating β-catenin/c-Myc signaling.
Wang KX; Du GH; Qin XM; Gao L
Phytomedicine; 2021 Dec; 93():153781. PubMed ID: 34649212
[TBL] [Abstract][Full Text] [Related]
12. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
[TBL] [Abstract][Full Text] [Related]
13. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in genes of the de novo lipogenesis pathway and overall survival of hepatocellular carcinoma patients undergoing transarterial chemoembolization.
Wu YS; Bao DK; Dai JY; Chen C; Zhang HX; Yang Y; Xing JL; Huang XJ; Wan SG
Asian Pac J Cancer Prev; 2015; 16(3):1051-6. PubMed ID: 25735330
[TBL] [Abstract][Full Text] [Related]
15. Targeting metabolic reprogramming in hepatocellular carcinoma to overcome therapeutic resistance: A comprehensive review.
Wang Q; Liu J; Chen Z; Zheng J; Wang Y; Dong J
Biomed Pharmacother; 2024 Jan; 170():116021. PubMed ID: 38128187
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Reprogramming and Risk Stratification of Hepatocellular Carcinoma Studied by Using Gas Chromatography-Mass Spectrometry-Based Metabolomics.
Fang C; Wang H; Lin Z; Liu X; Dong L; Jiang T; Tan Y; Ning Z; Ye Y; Tan G; Xu G
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008393
[TBL] [Abstract][Full Text] [Related]
17. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
[No Abstract] [Full Text] [Related]
18. Aerobic glycolysis enhances HBx-initiated hepatocellular carcinogenesis via NF-κBp65/HK2 signalling.
Chen L; Lin X; Lei Y; Xu X; Zhou Q; Chen Y; Liu H; Jiang J; Yang Y; Zheng F; Wu B
J Exp Clin Cancer Res; 2022 Nov; 41(1):329. PubMed ID: 36411480
[TBL] [Abstract][Full Text] [Related]
19. Switching of pyruvate kinase isoform L to M2 promotes metabolic reprogramming in hepatocarcinogenesis.
Wong CC; Au SL; Tse AP; Xu IM; Lai RK; Chiu DK; Wei LL; Fan DN; Tsang FH; Lo RC; Wong CM; Ng IO
PLoS One; 2014; 9(12):e115036. PubMed ID: 25541689
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of a hub gene prognostic index for hepatocellular carcinoma.
Shi Q; Meng Z; Tian XX; Wang YF; Wang WH
Future Oncol; 2021 Jun; 17(17):2193-2208. PubMed ID: 33620260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
